Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year
-
Mehbooba Mufti urges dialogue and renewed Central Asia links for Kashmir
-
Bezos grant helps Seattle nonprofit move thousands of families toward housing
-
Seacliff Healthcare Seeks Specialist GP in Thirroul
-
Shrini Srivastava joins crew of Varanasi-Delhi Vande Bharat Sleeper service
-
US stocks fall before midterm Election Day as technology shares weaken
-
Nearly Half of Australian Workers Overqualified, Survey Finds
-
BLS Polymers makes strong market debut at ₹248 per share
-
RBI eases export-declaration compliance for individual service exporters
-
Petrol and diesel prices remain broadly steady across major Indian cities
-
India proposes more import entry points for drugs and medical devices
-
Reliance shares remain in focus after near-12% surge
-
Derek Tierney Outlines Ten-Year Strategy for National Digital Health System
-
2026 Arizona Midterms: Key Races, Ballot Measures, and Voter Deadlines
-
NBC’s Steve Kornacki Reveals Tech Habits Ahead of Midterm Elections
-
Coal India prepares possible $1 billion Mahanadi Coalfields listing
-
India and Israel oppose UN draft on regional conventional arms control
-
Julia Stiles and Ezra Sosa Share Emotional Farewell After 'DWTS' Elimination
-
BLS Polymers shares open 65.3% above IPO price
-
US Buildings Threatened by Wildfires Could Triple by 2060
-
Capital-markets shares rally as Motilal Oswal and Angel One lead gains
-
Why Pregnancy Cost Estimates Fail: A Family’s $9,000 Surprise
-
Latino Voters Defy ICE Fears, Turn Out in Record Numbers for Midterms
-
US Strikes Iranian Targets in Strait of Hormuz Ahead of Midterms
-
ITC shares rise as analysts anticipate gradual cigarette-business recovery
-
Brodeur’s Overtime Goal Secures Bethlehem’s Second Consecutive Sectional Title
-
Reliance rally puts historical one-year return pattern in focus
-
Rare 1970 Plymouth ‘Cuda 426 Hemi Listed for $400,000
-
Kuwait edges Oman 1-0 in veterans Gulf Cup in Doha
-
The Digital Burden: Why Instant Messaging Feels Like a Full-Time Job
-
Saudi Aramco quarterly profit climbs 34.6% amid elevated oil prices
-
Alberta Tabled Controversial Riding Boundary Maps Amid Gerrymandering Accusations
-
Washington reports movement in Iran negotiations aimed at preventing escalation
-
Hong Kong court set to sentence activist Joshua Wong in security case
-
Korea’s Labor Share of GDP Hits Record Low Amid Semiconductor Boom
-
Australia raises benchmark rate to highest level in 18 years
-
littlefish and Halo Dot Partner to Replace Payment Terminals with SoftPOS
-
'The Remarried Empress' Cast Discusses Bringing Fantasy Royal Drama to Life
-
Kuwait inspectors destroy 115 kilograms of unverified meat in Farwaniya
-
Asian stocks retreat as AI worries outweigh steep oil-price drop
-
Egypt Accelerates Construction of 341km Sinai Railway Linking Arish and Taba
-
Hamad International Airport stages emergency drills during WATAN 2026
-
John Schneider Admits Owes Millions in 'Dukes of Hazzard' Divorce Battle
-
Global failure to punish attacks leaves journalists at continuing risk
-
Philippine Authorities Report Progress in Thomas Markle Sr. Child Pornography Probe
-
Researchers Warn 'Bookkeeping Trick' Masks Beef Industry's Methane Emissions
-
Web Summit Qatar 2026 generated QR1 billion economic impact, report says
-
Climate Change Intensified Atlantic Hurricanes, Study Finds
-
UAE oil spill raises questions for desalination operations
-
Qatar solar expansion opens scope for technical performance gains
-
Doha hotel and Carolina Herrera launch fragrance-inspired afternoon tea
Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year
FORT LAUDERDALE, FL / ACCESS Newswire / April 6, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) ("Sunshine Biopharma" or the "Company"), a pharmaceutical company offering and developing life‑saving medicines across oncology, antivirals, and other key therapeutic areas, today announced the filing of its Annual Report on Form 10‑K for the fiscal year ended December 31, 2025.
2025 Highlights
Revenue of $36.3 million, representing a 4.1% increase compared to 2024.
$2.46 million in gross proceeds raised through a registered direct offering to support expansion of sales operations.
Nine new generic prescription drugs launched, expanding the Company's portfolio in oncology, cardiovascular health, central nervous system disorders, and antimicrobials.
Advancement of proprietary antiviral research, including a new series of orally active, non‑covalent PLpro protease inhibitors that demonstrated dose‑dependent antiviral activity in SARS‑CoV‑2‑infected mice, strong potency in cellular models, and favorable pharmacokinetics.
Management Commentary
"We are pleased with our accomplishments in 2025, as we remain committed to reaching profitability in the near future," said Dr. Steve Slilaty, CEO. "Looking ahead, we are excited about the opportunities for growth in 2026 and beyond as we continue expanding our generic drug portfolio and advancing our proprietary drug development programs to deliver more life‑saving medicines to the market."
Financial Summary (in millions)
2025 | 2024 | |
|---|---|---|
Revenue | $36.31 | $34.87 |
Gross Profit | $12.26 | $10.67 |
General & Administrative Expenses | $18.48 | $16.48 |
Net Loss | $5.98 | $5.13 |
The increase in General & Administrative Expenses in 2025 was primarily driven by a non‑cash, non‑recurring impairment charge of $1.75 million related to intangible assets. Excluding this charge, the Company's operating performance reflects a meaningful improvement over 2024.
In January 2026, Sunshine Biopharma implemented cost‑reduction initiatives aimed at lowering general and administrative expenses and sharpening the Company's focus on achieving near‑term profitability. Based on current plans, these initiatives are expected to reduce expenses by approximately $2 million to $3 million in 2026, although there can be no assurance that these reductions will be fully realized.
About Sunshine Biopharma
Sunshine Biopharma currently markets 71 generic prescription drugs in Canada, with 12 additional launches planned for the remainder of 2026. The Company is also advancing two proprietary drug development programs:
K1.1 mRNA, an mRNA‑Lipid Nanoparticle therapeutic candidate targeting liver cancer.
PLpro protease inhibitor, a small‑molecule antiviral candidate for SARS‑related coronavirus infections.
Additional information is available at www.sunshinebiopharma.com.
Forward‑Looking Statements
This press release contains forward‑looking statements based on current expectations, forecasts, and assumptions that involve risks and uncertainties. These statements include, but are not limited to, those regarding the Company's financial performance, drug development activities, and future growth opportunities. Actual results may differ materially due to various risks and uncertainties described in the Company's filings with the U.S. Securities and Exchange Commission. Readers are encouraged to review the Company's most recent SEC filings for additional information.
Contact:
Camille Sebaaly, CFO
Direct Line: 514‑814‑0464
[email protected]
SOURCE: Sunshine Biopharma Inc.
View the original press release on ACCESS Newswire
Y.Kobayashi--AMWN